Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Cancer Research

• Publication date

  1998-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 9699658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The urokinase‐type plasminogen activator system in cancer metastasis: A review

  1997cited by this paper
• ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.

  1997cited by this paper
• The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction

  1997cited by this paper
• Cell-surface acceleration of urokinase-catalyzed receptor cleavage.

  1997cited by this paper
• 128 A cellular GPI-specific phospholipase D regulates the biological function of the urokinase receptor

  1997cited by this paper
• The urokinase receptor is a major vitronectin-binding protein on endothelial cells.

  1996cited by this paper
• Regulation of Integrin Function by the Urokinase Receptor

  1996cited by this paper
• The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria

  1995cited by this paper
• Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies

  1995cited by this paper
• Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.

  1994cited by this paper
• A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumors

  1994cited by this paper
• Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.

  1994cited by this paper
• Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay.

  1994cited by this paper
• Screening for ovarian cancer: the role of noninvasive imaging techniques.

  1994cited by this paper
• Identification of the urokinase receptor as an adhesion receptor for vitronectin.

  1994cited by this paper
• Urokinase and urokinase receptor expression in somatic cell hybrids

  1994cited by this paper
• Urokinase receptor and colorectal cancer survival.

  1994cited by this paper
• The plasminogen‐activation system in ovarian tumors

  1993cited by this paper
• A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

  1993cited by this paper
• Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.

  1993cited by this paper
• Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.

  1992cited by this paper
• cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator.

  1992cited by this paper
• Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor

  1991cited by this paper
• Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours.

  1991cited by this paper
• Protein Structure and Membrane Anchorage of the Cellular Receptor for Urokinase-Type Plasminogen Activator

  1991cited by this paper
• The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator.

  1991cited by this paper
• Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

  1991cited by this paper
• The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.

  1990cited by this paper
• The CA 125 tumour-associated antigen: a review of the literature.

  1989cited by this paper
• Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.

  1985cited by this paper
• A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase

  1985cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• The role of suPAR and related proteins in kidney, heart diseases, and diabetes

  2026cites this paper
• suPAR as a biomarker of support in different clinical settings.

  2025cites this paper
• Aberrant glycosylation of α3 integrins as diagnostic markers in epithelial ovarian cancer.

  2023cites this paper
• COVID-19 biomarkers and their overlap with comorbidities in a disease biomarker data model

  2021cites this paper
• COVID-19 Biomarkers in research: Extension of the OncoMX cancer biomarker data model to capture biomarker data from other diseases.

  2020cites this paper
• The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers.

  2019cites this paper
• Relating GPI-Anchored Ly6 Proteins uPAR and CD59 to Viral Infection

  2019cites this paper
• Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus

  2017cites this paper
• Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor – β1 (TGF-β1) and potential effects on migration and invasion

  2017cites this paper
• An ELISA method detecting the active form of suPAR.

  2016cites this paper
• The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia

  2016cites this paper
• Synthesis of New Ligands of UrokinaseReceptor and New Urotensin-IIDerivatives

  2015cites this paper
• Oral Squamous Cell Carcinoma - Role of the Plasminogen Activation System in Tumour Progression.

  2015cites this paper
• Tumour Microenvironments Induce Expression of Urokinase Plasminogen Activator Receptor (uPAR) and Concomitant Activation of Gelatinolytic Enzymes

  2014cites this paper
• Proteomic Analysis of Ovarian Cancer Tumor Fluid is a Rich Source ofPotential Biomarkers

  2014cites this paper
• Apolipoprotein Concentrations Are Elevated in Malignant Ovarian Cyst Fluids Suggesting That Lipoprotein Metabolism Is Dysregulated in Epithelial Ovarian Cancer

  2013cites this paper
• Role of Urokinase Receptor in Tumor Progression and Development

  2013cites this paper
• Ovarian Cyst Fluids Are a Cache of Tumor Biomarkers That Include Calgranulin A and Calgranulin B Isoforms

  2013cites this paper
• metalloproteinase-12: implication for angiogenesis in fibrin matrices Proteolysis of the urokinase-type plasminogen activator receptor by

  2013cites this paper
• Urokinase‐Type Plasminogen Activator, Its Receptor and Inhibitor as Biomarkers in Cancer

  2012cites this paper
• Aspects on sepsis : treatment and markers

  2012cites this paper
• Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers

  2012cites this paper
• Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels

  2011cites this paper
• Regulation of cell signalling by uPAR

  2010cites this paper
• Soluble urokinase plasminogen activator receptor and cardiovascular function in African and Caucasian populations : the SAfrEIC study

  2010cites this paper
• Novel protein interactors of urokinase-type plasminogen activator receptor.

  2010cites this paper
• Estradiol Attenuates EGF-Induced Rapid uPAR Mobilization and Cell Migration via the G-protein-Coupled Receptor 30 in Ovarian Cancer Cells

  2009cites this paper
• Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.

  2009cites this paper
• Quantification of Urokinase Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor Type 1 (PAI-1) mRNA in Breast Cancer Tissue

  2009cites this paper
• suPAR: The Molecular Crystal Ball

  2009cites this paper
• Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer.

  2008cites this paper
• The Urokinase Plasminogen Activator Receptor as a Target for Cancer Therapy

  2008cites this paper
• Expression of Kallikrein 7 Diminishes Pancreatic Cancer Cell Adhesion to Vitronectin and Enhances Urokinase-Type Plasminogen Activator Receptor Shedding

  2008cites this paper
• hematopoietic stem cell mobilization Involvement of the urokinase-type plasminogen activator receptor in

  2008cites this paper
• The Plasminogen Activation System as a Source of Prognostic Markers in Cancer

  2008cites this paper
• Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer

  2008cites this paper
• Urokinase receptor variants in tissue and body fluids.

  2007cites this paper
• Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer.

  2007cites this paper
• EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.

  2006cites this paper
• Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.

  2006cites this paper
• Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC)

  2006cites this paper
• Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR).

  2006cites this paper
• TITLE: Novel Protein Microarray Technology to Examine Men with Prostate Cancer

  2006cites this paper
• Role of Urokinase-Type Plasminogen Activator Receptor in Human Glioma Invasion

  2005cites this paper
• Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization.

  2005cites this paper
• Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?

  2005cites this paper
• Tumorassoziierte Prognosefaktoren der Plasminogenaktivator-Familie

  2005cites this paper
• Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer

  2004cites this paper
• Receptor-Like 1 and -Like 2 Is an Endogenous Ligand for Formyl Peptide through a Urokinase Receptor Epitope That Urokinase Induces Basophil Chemotaxis

  2004cites this paper
• Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.

  2004cites this paper
• GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy

  2004cites this paper
• Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.

  2004cites this paper
• The urokinase receptor as a potential target in cancer therapy.

  2004cites this paper
• The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.

  2004cites this paper
• Urokinase Induces Basophil Chemotaxis through a Urokinase Receptor Epitope That Is an Endogenous Ligand for Formyl Peptide Receptor-Like 1 and -Like 21

  2004cites this paper
• High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer

  2003cites this paper
• Plasminogen: Structure, Activation, and Regulation

  2003cites this paper
• Inhibitory Effects of Progesterone on Plasma Membrane Fluidity and Tumorigenic Potential of Ovarian Epithelial Cancer Cells

  2003cites this paper
• Possible role of matriptase in the diagnosis of ovarian cancer

  2003cites this paper
• The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy

  2003cites this paper
• Role of Plasminogen Activation in Hematopoietic Malignancies and in Normal Hematopoiesis

  2003cites this paper
• Urokinase Plasminogen Activator Receptor and Soluble Matrix Metalloproteinase-9 in Acute Myeloid Leukemia Patients: A Possible Relation to Disease Invasion

  2003cites this paper
• Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.

  2002cites this paper
• Calpain is required for MMP-2 and u-PA expression in SV40 large T-antigen-immortalized cells.

  2002cites this paper
• Metalloproteases Cleave the Urokinase-Type Plasminogen Activator Receptor in the D1-D2 Linker Region and Expose Epitopes not Present in the intact Soluble Receptor

  2002cites this paper
• Ovarian cancer-associated proteinases.

  2002cites this paper
• The Cleavage of the Urokinase Receptor Regulates Its Multiple Functions*

  2002cites this paper
• Urokinase, Urokinase Receptor, and ICAMs in Human Leukemia

  2001influential citation
• High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane.

  2001cites this paper
• Release of Soluble Urokinase Receptor from Vascular Cells*

  2001cites this paper
• Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI‐1)

  2001cites this paper
• Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices.

  2001cites this paper
• Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.

  2001cites this paper
• DEDIFFERENTIATIO NO FSEROU SOVARIA NCANCE RFRO MCYSTI CTO SOLI DTUMOR SI SASSOCIATE DWIT HINCREASE DEXPRESSIO NO FmRNA FO RUROKINAS EPLASMINOGE NACTIVATO R(uPA) ,IT SRECEPTO R(uPAR) AN DIT SINHIBITO R(PAI-1)

  2001cites this paper
• High Level Synthesis of Recombinant Soluble Urokinase Receptor (CD87) by Ovarian Cancer Cells Reduces Intraperitoneal Tumor Growth and Spread in Nude Mice

  2001cites this paper
• High Level Synthesis of Recombinant Soluble Urokinase Receptor (CD87) by Ovarian Cancer Cells Reduces Intraperitoneal Tumor Growth and Spread in Nude Mice

  2001cites this paper
• Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling

  2001cites this paper
• Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells

  2000cites this paper
• Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo

  2000cites this paper
• The plasminogen activation system in tumor growth, invasion, and metastasis

  2000cites this paper
• Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.

  2000cites this paper
• New ELISA for quantitation of human urokinase receptor (CD87) in cancer.

  2000cites this paper
• Decrease Rapidly during Chemotherapy Circulating Tumor Cells in Acute Myeloid Leukemia and Soluble Urokinase Receptor Levels Correlate with Number of Updated Version

  2000cites this paper
• Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors.

  1999cites this paper
• Blast Cell-surface and Plasma Soluble Urokinase Receptor in Acute Leukemia Patients: Relationship to Classification and Response to Therapy

  1999cites this paper
• Cellular glycosylphosphatidylinositol‐specific phospholipase D regulates urokinase receptor shedding and cell surface expression

  1999cites this paper
• Urokinase receptor cleavage and shedding : occurrence and consequences.

  1999influential citation